Abstract
Brodalumab, a human monoclonal antibody, das been approved for treatment of moderate to severe plaque psoriasis in July 2017. Three phase-III-studies demonstrate that the therapy with brodalumab results in clinical improvement compared to placebo. In addition, the antibody was more efficient compared to ustekinumab regarding several clinical parameteres.
Author supplied keywords
Cite
CITATION STYLE
APA
Sonnet, M. (2018, May 1). Brodalumab. Arzneimitteltherapie. Wissenschaftliche Verlagsgesellschaft mbH. https://doi.org/10.1007/s40278-025-74478-z
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free